Disease Domain | Count |
---|---|
Neoplasms | 11 |
Nervous System Diseases | 4 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Diagnostic radiopharmaceuticals | 12 |
Small molecule drug | 9 |
Radionuclide Drug Conjugates (RDC) | 2 |
Bispecific antibody | 1 |
Enzyme | 1 |
Target- |
Mechanism SPECT |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date03 Jul 1992 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CaM modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date15 Oct 2024 |
Sponsor / Collaborator |
Start Date10 Oct 2024 |
Sponsor / Collaborator |
Start Date27 Sep 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
HYNIC-3PRGD2(Foshan Rui Diao) | - | NDA/BLA |
Recombinant human Calcineurin B subunit(Haikou Qili Pharmaceutical) ( CaM ) | Liver Cancer More | Phase 2 Clinical |
99mTc N-Isonitrile Glucosamine | Non-Small Cell Lung Cancer More | Phase 1 |
99mTcN-Isonitrile glucose | Neoplasms More | Phase 1 |
[18F]FBFP ( σ1 receptor ) | Alzheimer Disease More | Preclinical |